000			04483namaa22004571i 4500
003			EG-GICUC
005			20260416122922.0
008			260405s2025 ua a|||frm||| 000 0 eng d
040			_aEG-GICUC _beng _cEG-GICUC _dEG-GICUC _erda
041	0		_aeng _beng _bara
049			_aDeposit
082	0	4	_a615.9
092			_a615.9 _221
097			_aPh.D
099			_aCai01.08.09.Ph.D.2025.Ni.P
100	0		_aNibrass Taher Hussein Abdali, _epreparation.
245	1	0	_aPharmacological study of the role of uric acid lowering agents on testosterone-induced benign prostatic hypertrophy via akt/ mtor signaling pathway / _cby Nibrass Taher Hussein Abdali ; Supervision Prof. Dr. Hala Fahmy Zaki, Prof. Dr. Laila Ahmed Abdelaziz, Dr. Yasmin Shokr Mohamed, Dr. Hassan Afify Hassan.
246	1	5	_aدراسة دوائية لدور عامل خفض حمض اليوريك على تضخم البروستات الحميد المحدث بالتستوستيرون من خلال مسار أكت/إم تور
264		0	_c2025.
300			_a119 pages : _billustrations ; _c25 cm. + _eCD.
336			_atext _2rda content
337			_aUnmediated _2rdamedia
338			_avolume _2rdacarrier
502			_aThesis (Ph.D)-Cairo University, 2025.
504			_aBibliography: pages 96-119.
520		3	_aBenign prostatic hyperplasia is the most common urological condition among elderly men. Because of modifiable metabolic risk factors, the prevalence of benign prostatic hyperplasia is rising. Emerging evidence links elevated uric acid levels to prostatic inflammation and hyperplasia, potentially through oxidative stress and activation of proliferative pathways. Tart-cherry and eugenol were not previously investigated against benign prostatic hyperplasia (BPH). Eighty healthy male Wistar rats were utilized in the current study and subdivided randomly into ten groups (n=8). BPH was induced by administering testosterone (3 mg/kg; s.c.) for 2 weeks. This was done either alone or after one-week pretreatment with probenecid (200 mg/kg/day; i.p), tart-cherry (500 mg/kg/day; p.o.), eugenol (10 mg/kg/day; p.o.), or a combination of these agents. At the end of the experiment, the prostate tissue was used for biochemical analysis, reverse transcriptase polymerase chain reaction, Western blot analysis, and histological and immunohistochemical assessment The results revealed a significant increase in prostate index, along with upregulation of cell survival markers ‎like cyclin D1 and characteristic histopathological changes indicative of BPH post-testosterone administration. ‎Additionally, testosterone induced elevated uric acid levels, oxidative stress, inflammatory markers, and ‎activation of pro-survival pathways including PI3-K/AKt/mTOR and NFκB. However, intervention with ‎probenecid, tart-cherry, eugenol adminsterd individually or in combination effectively mitigated these changes, showcasing their anti-‎inflammatory, antioxidative, and anti-hyperproliferative properties. Notably, the combination therapy ‎demonstrated superior efficacy compared to individual treatments.
520		3	_aخلصت الدراسة إلى أن إعطاء البروبنيسيد والكرزالمرّ والإيوجينول، سواء بشكل منفرد أو مجتمع، قد أظهر تأثيرًا وقائيًا ضد فرط تنسج البروستات الحميد المحفز بالتستوستيرون في الفئران، مما يوفر نهجًا متعدد الأهداف يشمل مكافحة الالتهاب، تقليل الإجهاد التأكسدي، وكبح مسارات تكاثر الخلايا.
530			_aIssues also as CD.
546			_aText in English and abstract in Arabic & English.
650		0	_aToxicology
650		0	_aعلم السموم
653		1	_abenign prostatic hyperplasia _atart cherry _aeugenol _ainflammation _aprobenecid _atestosterone _aتضخم البروستات الحميد _aالكرز الحامض
700	0		_aHala Fahmy Zaki _ethesis advisor.
700	0		_aLaila Ahmed Abdelaziz _ethesis advisor.
700	0		_aYasmin Shokr Mohamed _ethesis advisor.
700	0		_aHassan Afify Hassan _ethesis advisor.
900			_b01-01-2025 _cHala Fahmy Zaki _cLaila Ahmed Abdelaziz _cYasmin Shokr Mohamed _cHassan Afify Hassan _UCairo University _FFaculty of Pharmacy _DDepartment of Pharmacology & Toxicology
905			_aShimaa _eEman Ghareb
942			_2ddc _cTH _e21 _n0
999			_c179222